Angioimmunoblastic T-Cell Lymphoma Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies – Celgene, Verastem, Beigene, Merck, and Solasia Pharma

January 19 15:54 2022
Angioimmunoblastic T-Cell Lymphoma Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies - Celgene, Verastem, Beigene, Merck, and Solasia Pharma
Delveinsight Business Research LLP
DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Angioimmunoblastic T-Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Angioimmunoblastic T-Cell Lymphoma Market

Angioimmunoblastic T-Cell Lymphoma: An Overview

Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. PTCL is classified as a subtype of non-Hodgkin’s lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. PTCL specifically affects T-cells and results when T-cells develop and grow abnormally.

Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). The exact, underlying cause of Angioimmunoblastic T-Cell Lymphoma is unknown. It is believed that a dysfunctional immune system response to an unknown antigen ultimately leads to the development of the disorder.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

Angioimmunoblastic T-Cell Lymphoma Market Key Facts

  • As per DelveInsight estimates, the incident cases of PTCL in the 7MM were 16,298 cases in 2017. The cases are expected to increase at a significant rate during the forecast period.

  • As per the Epidemiology report of DelveInsight, out of the total Incident cases of PTCL (6,110) in the US, nearly 1,380 cases were estimated for Angioimmunoblastic T-cell Lymphoma (AITL) in 2017.

  • Estimates suggested that the United States accounts for 37.5% of all incident cases of PTCL among the 7MM. In 2017, there were a total of 6,110 incident cases of PTCL in the US, which are anticipated to increase during the forecast period (2020-2030).

  • Among the EU-5, the highest cases of Angioimmunoblastic T-Cell Lymphoma were estimated in Germany with 344 cases in 2017.
  • In France, out of the total Incident cases of PTCL (947), nearly 342 cases were estimated for Angioimmunoblastic T-cell Lymphoma (AITL) in 2017.

  • The incident population of PTCL in Japan is increasing at a rate of 1.01%, during the study period, i.e. 2017-2030 thereby occupying the second-highest position amongst the 7MM. For Angioimmunoblastic T-Cell Lymphoma, Japan has accounted for nearly 538 Incident cases in 2017. 

Angioimmunoblastic T-Cell Lymphoma Market

The Angioimmunoblastic T-Cell Lymphoma market size is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Angioimmunoblastic T-Cell Lymphoma market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.

The report gives a thorough detail of the Angioimmunoblastic T-Cell Lymphoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Angioimmunoblastic T-Cell Lymphoma Epidemiology

The epidemiology section covers insights about the historical and current Angioimmunoblastic T-Cell Lymphoma patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Angioimmunoblastic T-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Angioimmunoblastic T-Cell Lymphoma market or expected to get launched in the market during the study period. The analysis covers Angioimmunoblastic T-Cell Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Angioimmunoblastic T-Cell Lymphoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Angioimmunoblastic T-Cell Lymphoma Therapeutics Analysis

The dynamics of the Angioimmunoblastic T-cell Lymphoma (AITL) market is anticipated to change in the coming years owing to the rise in healthcare spending across the world.

The key companies in the Angioimmunoblastic T-Cell Lymphoma market include:

  • Celgene

  • Verastem

  • Beigene

  • Merck

  • Solasia Pharma

  • Kura Oncology

And others

Angioimmunoblastic T-Cell Lymphoma therapies covered in the report include:

  • Azacitidine (CC-486)

  • Copiktra (Duvelisib)

  • Tislelizumab (BGB-A317)

  • SP-02 (darinaparsin)

  • Tipifarnib

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- Angioimmunoblastic T-Cell Lymphoma Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. Angioimmunoblastic T-Cell Lymphoma Competitive Intelligence Analysis

4. Angioimmunoblastic T-Cell Lymphoma Market Overview at a Glance

5. Angioimmunoblastic T-Cell Lymphoma Disease Background and Overview

6. Angioimmunoblastic T-Cell Lymphoma Patient Journey

7. Angioimmunoblastic T-Cell Lymphoma Epidemiology and Patient Population

8. Angioimmunoblastic T-Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Angioimmunoblastic T-Cell Lymphoma Unmet Needs

10. Key Endpoints of Angioimmunoblastic T-Cell Lymphoma Treatment

11. Angioimmunoblastic T-Cell Lymphoma Marketed Products

12. Angioimmunoblastic T-Cell Lymphoma Emerging Therapies

13. Angioimmunoblastic T-Cell Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Angioimmunoblastic T-Cell Lymphoma Market Outlook (7 major markets)

16. Angioimmunoblastic T-Cell Lymphoma Access and Reimbursement Overview

17. KOL Views on the Angioimmunoblastic T-Cell Lymphoma Market.

18. Angioimmunoblastic T-Cell Lymphoma Market Drivers

19. Angioimmunoblastic T-Cell Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: